TARSUS PHARMACEUTICALS, INC. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$451M
R&D
$64M
SG&A
$427M
D&A
$855K
Operating Income
$-71M
EBITDA
$-70M
Interest Expense
$9M
Other Income/Expense
$16M
Pretax Income
$-64M
Tax Provision
$2M
Net Income
$-66M
Operating Margin
-15.7%
Net Margin
-14.7%
Effective Tax Rate
-3.2%
Revenue YoY Variation
146.7%
Income YoY Variation
41.1%